Screener
Adaptive Biotechnologies ADPT Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| General and administrative | 20,984 | 17,399 |
| Amortization of intangible assets | 419 | 419 |
| Total operating expenses | 90,080 | 82,047 |
| Loss from operations | (19,206) | (29,604) |
| Interest and other income, net | 2,080 | 2,679 |
| Interest expense | (2,889) | (2,905) |
| Net loss | (20,015) | (29,830) |
| Add: Net income attributable to noncontrolling interest | (18) | (22) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Adaptive Biotechnologies's operating income?
- Adaptive Biotechnologies (ADPT) reported operating income of -$19.21M in Q1 2026.
- How has Adaptive Biotechnologies's operating income changed year-over-year?
- Adaptive Biotechnologies's operating income increased by 35.1% year-over-year, from -$29.6M to -$19.21M.
- What is the long-term trend for Adaptive Biotechnologies's operating income?
- Over 4 years (2021 to 2025), Adaptive Biotechnologies's operating income has grown at a -27.7% compound annual growth rate (CAGR), from -$208.97M to -$57.12M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Adaptive Biotechnologies's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude